Paper3978620
Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
Reddel RR and 3 others. Cancer Res, 1985. Cited by 190 papers, by iCite.
Cite this record
ConductScience Library. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Papers, record 3978620. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3978620
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Receptors, Drug | Major topic |
| Tamoxifen | Major topic |
| Cell Cycle | |
| Cell Division | |
| Cell Line | |
| Estradiol | |
| Female | |
| Humans | |
| Receptors, Estrogen |
Source PubMed
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 190 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42577427 | Shu Gan Jie Yu herbal combination enhances tamoxifen sensitivity in breast cancer cells via modulation of the SNCG/p-ERα,mTOR /AKT and p-ERK pathway. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42577427 | PubMed |
| 39060878 | Failure to progress: breast and prostate cancer cell lines in developing targeted therapies. | Cancer Metastasis Rev | 2024 | https://conductscience.org/library/papers/39060878 | PubMed |
| 38138584 | Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL). | Molecules | 2023 | https://conductscience.org/library/papers/38138584 | PubMed |
| 35745897 | Mechanistic Approach of Nano Carriers for Targeted in Cancer Chemotherapy: A Newer Strategy for Novel Drug Delivery System. | Polymers (Basel) | 2022 | https://conductscience.org/library/papers/35745897 | PubMed |
| 33542078 | Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33542078 | PubMed |
| 31138120 | Efficient estimation of grouped survival models. | BMC Bioinformatics | 2019 | https://conductscience.org/library/papers/31138120 | PubMed |
| 30760083 | Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact. | RNA Biol | 2019 | https://conductscience.org/library/papers/30760083 | PubMed |
| 29167821 | PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells. | NPJ Breast Cancer | 2017 | https://conductscience.org/library/papers/29167821 | PubMed |
| 28858267 | Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation. | Molecules | 2017 | https://conductscience.org/library/papers/28858267 | PubMed |
| 26892504 | Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex. | J Nanobiotechnology | 2016 | https://conductscience.org/library/papers/26892504 | PubMed |
| 25998416 | From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? | J Steroid Biochem Mol Biol | 2015 | https://conductscience.org/library/papers/25998416 | PubMed |
| 25874233 | Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer. | Biomed Res Int | 2015 | https://conductscience.org/library/papers/25874233 | PubMed |
| 25487036 | Plasmodium infection reduces the volume of the viral reservoir in SIV-infected rhesus macaques receiving antiretroviral therapy. | Retrovirology | 2014 | https://conductscience.org/library/papers/25487036 | PubMed |
| 23372829 | Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential. | PLoS One | 2013 | https://conductscience.org/library/papers/23372829 | PubMed |
| 23134774 | A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen. | BMC Syst Biol | 2012 | https://conductscience.org/library/papers/23134774 | PubMed |
| 21087932 | Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. | J Biol Chem | 2011 | https://conductscience.org/library/papers/21087932 | PubMed |
| 11091507 | Conventional Dose CAF Therapy versus Low Dose Adriamycin Therapy in the Treatment of Advanced Breast Cancer. | Breast Cancer | 1994 | https://conductscience.org/library/papers/11091507 | PubMed |
| 9746215 | The salubrious effect of tamoxifen [correction of Tamaxifen] on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer woman. | Mol Cell Biochem | 1998 | https://conductscience.org/library/papers/9746215 | PubMed |
| 9030250 | Combined effects of epirubicin and tamoxifen on the cell-cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells. | J Cancer Res Clin Oncol | 1997 | https://conductscience.org/library/papers/9030250 | PubMed |
| 8250600 | Effects of tamoxifen on human breast cancer cells in vitro. | Arch Gynecol Obstet | 1993 | https://conductscience.org/library/papers/8250600 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3978620
GET https://conductscience.org/api/papers/v1/3978620/cited_by?page=2